Tiziana Life Sciences (TLSA) said Friday it began dosing patients at its fifth clinical site at the Weill Cornell Medicine Multiple Sclerosis Center for a phase 2 trial evaluating intranasal foralumab to potentially treat multiple sclerosis.
The study, which focuses on patients with non-active secondary progressive multiple sclerosis, is already active at four other sites, including Yale and Johns Hopkins, the company said.
The trial aims to assess the safety and efficacy of foralumab, a fully human anti-CD3 monoclonal antibody delivered through the nose, Tiziana said.
After the blinded portion of the trial, all participants, including those on placebo, will receive the drug in a six-month open-label extension phase to evaluate long-term safety and benefits, the company said.
Shares of the company were up more than 7% in recent trading.
Price: 1.53, Change: +0.11, Percent Change: +7.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.